Gene Therapy Targets AIDS

For many years, a diagnosis of acquired immunodeficiency syndrome (AIDS) was a death sentence. It seemed unthinkable in the 1980s, but the medical community now largely treats the disease as a chronic illness. This profound shift arose through the development of highly active antiretroviral therapies (HAART). These medicines inhibit the replication and spread of the human immunodeficiency virus (HIV), which causes AIDS. They provide hope and new life to millions.

However, HAART comes with major side effects, such as fatigue, nausea, vomiting, diarrhea, fever, muscle pain, kidney and liver damage, heart disease, and insulin resistance. More significantly still, the treatment can never be completely effective. That’s because the HIV virus actually evades the treatment in two challenging ways:

  • High mutation rate: The HIV genome evolves rapidly. Its endless transformation changes the viral proteins that HAART works on, which renders the therapies ineffective. Nonetheless, patients try to stay ahead of the virus with daily medication.  In turn, pharmaceutical companies are continually working to develop new HIV drugs.
  • Latency: People with HIV typically have a reservoir of immune cells that contain inactive or latent HIV. In this state, the virus is essentially dormant and can remain so for years. However, at any time, latent microbes can reawaken and start making more HIV.

Because HAART targets only active virus, latency enables HIV to “hide.” Many in the field of HIV research consider tackling this viral reservoir the final frontier in successfully fighting the virus. This week, we focus on technology being developed by American Gene Technologies (AGT; Rockville, MD) to address chronic HIV infection.

Not Your Mother’s Gene Therapy

Scientists originally conceived of gene therapy as a way to treat disorders caused by a single genetic mutation, such as sickle cell disease, cystic fibrosis, or spinal muscular atrophy. This therapy can now address other kinds of illnesses, such as cancer and HIV. AGT is using gene therapy to eradicate latent HIV, and perhaps even eventually offer a cure.

Crippling The Immune System

How does HIV infect immune cells to begin with? HIV first destroys the immune system’s helper T-cells. These are specialized white blood cells that recognize a unique target, usually a specific protein on the surface of a pathogen. Once they lock on, the helper T’s release inflammatory cytokines—chemical messengers that help rev up the immune system. This includes activating cytotoxic or “killer” T-cells, which directly destroy invading microbes.

Without the helper T-cells, the immune system breaks down. That’s how HIV kills—by disabling the very cells that fight it. In fact, although HIV infects all types of helper T-cells, it appears to preferentially infect helper T-cells that are specific to HIV. After first wiping out those helper T’s, the virus can disable the rest. (Article continues below)

Do you seek a broad, intuitive understanding of the science involved in biopharma? Our 3-day BioImmersion: Biotech for the Non-Scientist course will give you the knowledge to hold your own in the biotech industry.   

Register Today – Only Offered Once in 2019!

                         Can’t make the face-to-face course? Check out our                             Biology of Biotech online course:

Engineering A Defense


AGT’s experimental treatment, AGT103-T, is designed to shore up those vulnerable helper T-cells by disabling latent HIV and preventing new infection. The new approach is a type of autologous cell therapy. That means doctors engineer a patient’s own cells to use as medicine, using the following steps:  

  • Isolate HIV-specific helper T-cells from patient blood;
  • Use gene therapy viral vector to deliver AGT103 to the isolated cells;
  • Expand treated cell population in the lab and infuse back into patient

The modified HIV-specific helper T-cells are now able to disable any latent virus that reawakens, while at the same time resist new infection. That means they can effectively fight any existing HIV-infected helper T-cells. The ultimate goal of the therapy is to enable HIV patients to effectively fight HIV infection while eliminating or reducing the need for HAART and its unwanted side effects. 

How does AGT103 make helper T-cells resistant to HIV? It is a type of gene therapy, only instead of delivering a gene that provides the recipe for a protein, it delivers genes that code for “antisense” RNAs—RNAs that disrupt the production of other proteins. The three proteins whose production is disrupted are:

  • CCR5, a protein on the surface of helper T-cells. HIV needs the protein in order to get inside them. Without CCR5, the cells will be resistant to infection.
  • Vif, or “viral infectivity factor,” an HIV protein. If a helper T-cell is already infected with HIV, knocking out vif makes it impossible for the virus to replicate itself.
  • Tat, or “trans activator of transcription,” another HIV protein required for the virus to make new proteins. No tat means no new viral proteins and no new virus.

AGT103 is preparing to enter clinical trials.

Cocktail Fodder: Turning HIV Against Itself?

The viral vector used by AGT derives from the HIV virus itself. Called lentiviral vectors, they’re also used to create CAR-T therapies.

Co Authors :

Sarah Van Tiem

Editor

Sarah Van Tiem began her career with Detroit Legal News, gaining unparalleled experience in public communication. Subsequent stints at Earthwatch Radio and Wisconsin Department of Natural Resources established Sarah as a respected writer/editor. Currently working as Editor for the Biotech Primer WEEKLY newsletter, Sarah is widely known for her expertise in science communication.

Share This